TEL AVIV, Dec 8- Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities could generate revenue of $1 billion to $1.5 billion by 2018..» Read More
VALKA, Latvia, Oct 29- From his office near Latvia's border, Valka deputy major Viesturs Zarins can see the future. Across a disused border post lies Estonia, a euro currency nation that Latvia will next year emulate. Latvia's adoption of the euro on January 1 may encourage investment and lower borrowing costs.
JERUSALEM, Oct 28- Teva Pharmaceutical Industries and Chief Executive Jeremy Levin denied an Israeli media report that Levin was considering resigning due to a rift with the company's board of directors.
Barbara Ryan, FTI Consulting managing director, breaks down the pharmaceutical company's earnings and weighs in on two promising drugs in the pipeline, as the company ramps up research and development.
Merck reported better-than-expected earnings, but sales of its Januvia diabetes treatment fell, raising more concerns about the company's growth prospects.
Channel 2 television quoted unnamed sources as saying there were strong differences of opinion between Levin and Chairman Phillip Frost over the implementation of Teva's new strategy.
Oct 25- AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, when booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more than offset lower demand for other medicines.
The drugmaker, split off at the beginning of the year from Abbott Laboratories Inc, on Friday said it had earned $964 million, or 60 cents per share, compared with $1.59 billion, or $1.01 per share, a year earlier. Sales rose 3.3 percent to $4.66 billion, above Wall Street expectations of $4.52 billion.
Oct 24- Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage trial. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment, fostamatinib, in June, which it licensed from Rigel in 2010..
NEW YORK, Oct 23- Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.
Oct 23- Eli Lilly and Co on Wednesday reported higher-than-expected quarterly earnings, helped by cost cuts and a big price increase for top-selling antidepressant Cymbalta, which begins facing generic competition in December.
Oct 23- Eli Lilly and Co on Wednesday reported better-than-expected quarterly earnings, helped by cost cuts and a big price increase for Cymbalta, its top-selling antidepressant that begins facing generic competition in December. The Indianapolis drugmaker earned $1.20 billion, or $1.11 per share, in the third quarter.
Oct 23- Eli Lilly and Co on Wednesday reported better-than-expected quarterly earnings, helped by cost cuts and strong growth of its drugs for depression, diabetes and. The Indianapolis drugmaker earned $1.20 billion, or $1.11 per share, in the third quarter. Company sales rose 6 percent to $5.78 billion, slightly above Wall Street expectations of $5.76 billion.
Oct 23- Eli Lilly and Co on Wednesday reported better-than-expected quarterly earnings, helped by cost cuts and strong growth of its drugs for depression, diabetes and. The Indianapolis drugmaker earned $1.20 billion, or $1.11 per share, in the third quarter.
Oct 22- Amgen Inc, which this month closed a nearly $10 billion acquisition of cancer drug maker Onyx Pharmaceuticals, reported higher-than-expected, third-quarter profit as results were helped by a large U.S. government order for one of its white blood cell boosters.
"Meaningful change is unlikely in the future," concluded the 14- member panel, assembled by Johns Hopkins University, in a report released on Tuesday that quickly drew protests from livestock industry groups.
*Full-year adjusted earnings forecast $0.95- $1.15/ share vs. est $0.96. Oct 22- Forest Laboratories Inc's new chief executive signaled strategic changes that will help the drugmaker focus on multiple new growth areas as it prepares to lose patent protection on another of its top-sellers.
Consumer goods group Reckitt Benckiser is reviewing options for its pharmaceuticals unit.
Andrew Weiss, head of pharma and biotech research at Vontobel, says most products in Novartis' pipeline will face tough competition and incur large marketing costs.
Concerns that flu could mean an increase in staff sick days has prompted some companies to arrange flu jabs for their employees – boosting sales for some drugs companies.
*CEO says growth in China still strong. ZURICH, Oct 17- Strong demand for Roche's speciality cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown in sales in China following a crackdown on sales practices there.